Screening and quantitative estimation of factor VIII inhibitors by Nijmegen-Bethesda assay in hemophilia a patient of Southern Odisha, India
DOI:
https://doi.org/10.18203/2349-3933.ijam20200075Keywords:
Bleeding disorder, Blood transfusion, Factor VIII inhibitors, Haemophilia, Nijmegen-Bethesda assayAbstract
Background: The current treatment of haemophilia is replacement of factor VIII or IX which is effective till development of inhibitor against factors. There has been no study on factor VIII inhibitors in Southern Odisha using Nijmegen–Bethesda assay. This study was planned with objectives to screen factor VIII inhibitors in hemophilia-A patients, to do quantitative estimation of it using Nijmegen-Bethesda assay and to explore factors associated with development of inhibitors.
Methods: This cross-sectional study was carried out from September 2016 to August 2018 in Department of pathology, MKCG medical college, Berhampur. Haemophilia-A patients coming to MKCG medical college and registered Haemophilia-A cases under Haemophilia society of Berhampur were included. Patients denying consent and having multiple clotting factors deficiencies were excluded. 1.8ml blood was collected. Mixing study was done to screen factor VIII inhibitors and then in positive cases inhibitors level measured by Nijmegen-Bethesda method. All data were analysed using SPSS (version 16.0).
Results: 70 cases of Hemophilia-A patients were studied. Majority (50%) were with severe hemophilia-A. 7 patients developed inhibitors where 3 were high and 4 were low responders. Inhibitor level ranged from 0.8 to 64 Nijmegen-Bethesda units. Patients with severe hemophilia A, more than 10 transfusions and who switched to receive recombinant FVIII from other blood products developed inhibitors which were significant.
Conclusions: Severity of hemophilia, increase frequency of transfusion and switching of blood products significantly increases chances of inhibitor development and hence intensive inhibitor screening is needed in these cases. Quantification of inhibitor is needed to monitor treatment and to manage bleeding episodes effectively.
References
Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Therapeutic Adv Hematol. 2013;4(1):59-72.
Bravo MI, Da Rocha‐Souto B, Grancha S, Jorquera JI. Native plasma derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors. Haemophilia. 2014;20(6):905-11.
Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P, et al. The epidemiology of FVIII inhibitors in Indian haemophilia A patients. Ind J Hematol Blood Transfus. 2014;30(4):356-63.
Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology and social costs of haemophilia in India. Ind J Med Res. 2014;140(1):19-31.
Hemophilia Federation (India). Available at: http://www.hemophilia.in. Accessed 15 Nov 2019.
Mohsin S, Jaffar J, Hussain S, Suhail S, Ullah MI, Amjad S. Detection of Factor VIII Inhibitors in Hemophilia A Patients. IJBC. 2012;4(4):163-8.
Dubey A, Verma A, Elhence P, Agarwal P. Evaluation of transfusion-related complications along with estimation of inhibitors in patients with hemophilia: A pilot study from a single center. Asian J Transfus Sci. 2013;7(1):8.
Sharifian R, Hoseini M, Safai R, Tugeh G, Ehsani AH, Lak M, et al. Prevalence of inhibitors in a population of 1280 hemophilia-A patients in Iran. Acta Medica Iranica. 2003;41(1):66-8.
Eshghi P, Mahadavi-Mazdeh M, Karimi M, Aghighi M. Haemophilia in the developing countries: the Iranian experience. Arch Med Sci. 2010;6(1):83-9.
Kraiem I, Hadhri S, Omri HE, Sassi R, Chaabani W, Ennabli S, et al. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs. Ann Biol Clin 2012;70(6):659-65.
Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964-97. Br J Haematol. 1999;104(4):909-14.
Company F, Rezaei N, Aliasgharpoor M. Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj. J Kermanshah Univ Med Sci. 2011;15(2):79379.
Kavakli K, Aktuğlu G, Kemahli S, Baslar Z, Ertem M, Balkan C, et al. Inhibitor screening for patients with hemophilia in Turkey. Turk J Hematol. 2006;23(1):25-32.
Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P, et al. The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients. Indian J Hematol Blood Transfus. 2014;30(4):356-63.
Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010;8(6):1256-65.
Lee CA, Berntorp EE, Hoots WK, eds. Textbook of hemophilia. 3rd ed. London, UK: John Wiley and Sons; 2014:256-268.
Rosendaal FR, Nieuwenhuis HK, Berg HMVD, Heijboer H, Bunschoten EPM, Meer JVDA, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993;81(8):2180-6.
